| |
January 2009 - Volume 3,
Issue 1
Effect of
ß- Thalassemia on Some Biochemical Parameters
 |
Nazdar Ezzaddin Rasheed1,
Salar Adnan Ahmed2
-
MBChB, MSc, Assistant Lecturer - Pediatric Department/
College of Medicine/ Hawler Medical University
- MSc. in Clinical Biochemistry-Dept.
of Clinical Biochemistry / College of Medicine / Hawler
Medical University
|
 |
|
ABSTRACT
Background
and objectives: Thalassemia or hemoglobinopathy
is a hereditary disease caused by defective globin synthesis
resulting in abnormal as well as decreased quantity
of globin chains. Ineffective erythropoiesis, hemolysis,
and increased red blood cell turnover.
The
present study deals with the effects of ß-thalassemia
on the following serum biochemical parameters (sodium,
potassium, calcium, phosphate and uric acid).
Material
and method: A prospective study was carried out
from September 2004 to March 2005 by collaboration between
clinical biochemistry and pediatric departments in College
of Medicine, Hawler Medical University on thirty patients
with ß-thalassemia in comparison with thirty normal
subjects.
Results:
The results showed that there was a significant difference
(P< 0.05) in the level of serum Potassium, Calcium,
Uric acid and hemoglobin while the differences in sodium
and phosphate were not significant.
Conclusion:
Based on findings of the present study it can be concluded
that ß-thalassemia causes multiple abnormalities
in biochemical parameters.
|
The thalassemia
syndrome is a group of metabolic inherited disorders(1)
characterized by microcytic hypochromic red blood cells. The
homozygous state, thalassemia major results in a severe anemia
and often death before puberty. The heterozygous state, thalassemia
minor is less severe and may be asymptomatic with little or
no anemia(2,3)
The word
thalassemia comes from the Greek "thalassa", sea
referring to thr Mediterranean and "haima", blood
which means blood disease of the sea(3,4,5). The
first description of severe thalassemia as a unique disorder
was described in 1925 by a Detroit pediatrician "Thomas
Cooley" who described a severe type of anemia in children
of Italian origin which was later named after him(3).
Thalassemia
represents the most common single gene disorder causing a
major public health problem(6)
It is widely
distributed through the Mediterranean, Middle East, India,
southeast Asia and Africa(5). Iraq is one of the
countries in which 6-10% of the population have hemoglobinopathy
of which thalassemia is a major part(7)
The underlying
abnormality in the thalassemia syndromes is thought to be
absence or reduction in production of hemoglobin(2)
There are
2 types of thalassemia - alpha and beta depending on which
globin chain is affected by genetic mutation or deletion(8).
The disease
is called beta thalassemia when ß chain production is
decreased relative to alpha chain production and alpha thalassemia
when a chain production is decreased relative to ß(2,
6).
Over the
last 3 decades the development of regular transfusion therapy
and iron chelating has dramatically improved the quality of
life however in the developing world, poor availability of
proper medical care, and safe and adequate red blood cell
transfusion, together with poor compliance to chelation therapy
remains a major obstacle. Despite the increased life expectancy
thalassemia complications keep arising especially iron overload
related complications as well as toxicities of iron chelator(9)
which may result in metabolic and endocrine abnormalities
like hypogonadism, diabetes mellitus, hypothyroidism, hypo-parathyroidism
and zinc and copper deficiency(10,11,12).
Precipitation
of alpha globin chains in the thalassemia RBC may interfere
with normal membrane function leading to increased calcium
content which is more pronounced in splenectomy patients correlates
with the degree of anemia(11).
1- Subjects
This study was conducted on 60 individuals all under 17 years,
thirty 30 of whom were patients with ß-thalassemia and
the other thirty 30 were healthy controls.
ß-Thalassemic
patients in Erbil were all registered in a pediatric hospital
thalassemic unit to receive treatment. The diagnosis of thalassemia
was based on hematological criteria (peripheral blood evaluation
and hemoglobin electrophoresis of the patients from early
years of life. The mean ± S.E of age was 11.93±1.1
years and the range 1-16 years. While the healthy individuals
mean ±S.E of age was 12.2±1.1 years and the
range 1-17 years - see Table 1
2-Blood sample collection:
Three to five millilitres of venous blood was drawn from ß-thalassemic
patients and healthy individuals. Collected blood was left
standing at room temperature until it clotted, then the sample
centrifuged at 300 rpm for 10 minutes for removal of serum
from suspended cells. Then the serum was tested for sodium,
potassium, calcium, phosphorous and uric acid determination.
|
Table (1): The host information of ß-thalassemiac
patients and reference group |
| Groups |
Total
Number |
Numbers |
Age (years) |
| Male |
Female |
Mean
±S.E |
Range |
| Group I |
30 |
14 |
16 |
12.2±1.1 |
1-17 |
| Group II |
30 |
12 |
18 |
11.93±1.1 |
1-16 |
3-Instruments
1- Spectrophotometer (Spectronic 21)
2- Centrifuge type Labofuge 200
3- Computer for data analysis
4- Flame photometer (Jenway)
4-Method
Sodium and potassium in Serum was measured by an instrument
called a Flame photometer according to Varly(13)
method as follows:
Principle of operation (Flame
photometry):-
Flame photometry relies upon the fact that the compounds of
the alkaline earth metals can be thermally dissociated in
a flame and that some atoms produced will be further excited
to a high energy level. When the atoms return to ground state
they emit radiation which lies mainly in the visible region
of the spectrum (each element emits radiation at a wave length
specific to that element(13) while routine biochemical
tests were done in serum for phosphorous determination according
to Gomorri methods(14).
Serum uric acid and calcium was determined
for both groups by an enzymatic colorimetry method by using
ready made kits Biomerieux Sa. (France) according to the method
of (Barhand and Coms) respectively(15, 16).
5-Statistical evaluation
Statistical analyses were carried out by using some statistical
measurements. Biochemical values were presented as the mean±S.EM
and range. All analyses for difference between the two independent
groups were performed by Student's t tests, with a level of
significance assigned at 0.05. Values less than 0.05 (P<0.05)
were considered to indicate statistical significance(17).
| Table (2): Biochemical parameters of the studied
group |
|
Parameters |
Unit |
Normal |
Patient |
Satistical
Evaluation |
| Range |
Mean±S.E |
Range |
Mean±S.E |
|
Potassium |
mmol/L |
3.2-6.4 |
4.8±0.1 |
3.6-7.5 |
5.3±0.2 |
P<0.05 |
|
Sodium |
mmol/L |
122-150 |
139±1.5 |
122-159 |
141±1.6 |
N.S |
| Calcium |
mg/dl |
8.7-15 |
11.3±0.3 |
2.4-6.6 |
4.6±0.2 |
P<0.01 |
| Phosphate |
mg/dl |
1.1-8 |
4.8±0.3 |
3.5-9.4 |
5.6±0.3 |
N.S |
| Uric
acid |
mg/dl |
2.8-8.6 |
4.6±0.2 |
3.8-91 |
5.9±0.3 |
P<0.01 |
| Hb |
g/dl |
13.9-8 |
11±0.1 |
8.4-4.8 |
7.5±0.2 |
P<0.01 |
| Age |
years |
1-17 |
12.2±1.1 |
1-16 |
11.93±1.1 |
N.S |
Group I (Healthy individuals):
The mean±S.E for serum Potassium gave values of 4.8±0.1
mmol/L and a range of 3.2-6.4 mmol/L. The mean±S.E
for serum Sodium was 139±1.5 mmol/L and the range was
122-150 mmol/L. The mean±S.E values for Calcium, Phosphorous
and Uric acid were 11.3±0.3, 4.8±0.3 and 4.6±0.2
mg/dl respectively, with the range of 8.7-15, 1.1-8 and 2.8-8.6
mg/dl respectively as shown in Table 1.
Group II (ß-thalassemic
patients):
The mean for serum Potassium gave values of 5.3±0.2
mmol/L and a range of 3.6-7.5. The mean for serum Sodium was
141±1.6 and the range was 122-159 mmol/L. The mean
value for Calcium, Phosphorous and Uric acid were 46±0.2,
5.6±0.3 and 5.9±0.3 mg/dl respectively, with
the range of 2.4-6.6, 3.5-9.4 and 3.8-91 mg/dl respectively
as shown in Table 2.
In comparison between healthy individuals
and ß-thalassemiac individuals, it was showed significant
differences in serum Potassium, Calcium, Uric acid and Hb
while serum phosphorous and sodium showed no significance
- see Table 2 Figure 1 and Figure2.
|

Figure(1):
Serum sodium and potassium in normal and ß-thalassemic
patients
|
|

Figure(2):
Serum total Calcium, Phosphate and Uric acid in
normal and ß- thalassemic patients
|
The goal
of the present study was to understand the effects of ß-thalassemia
on certain serum biochemical parameters (Sodium, potassium,
calcium, phosphate and uric acid).
The aim
of transfusion is to maintain a hemoglobin level that inhibits
ineffective erythropoiesis, marrow expansion and allow normal
growth. The hemoglobin should be maintained between 10-14
gm/dl with pre-transfusion hemoglobin of 10-11 gm/dl. Most
patients in the present study were suboptimally blood-transfused
thalassemics. They had significant anemia of 7.5±0.2g/dl
which resulted in growth retardation, delayed puberty, and
retarded bone age. These findings were in agreement with the
previous studies(1,18,19).
The results
obtained in this study as noted earlier showed that the mean
value [Mean±S.E.] of serum Potassium for ß-thalassemiac
patients was 5.3±0.2 mmol/L. The mean value for Uric
acid was 5.9±0.3 mg/dl. The values were significantly
higher in ß-thalassemiac patients compared with the
control group (p<0.05) which is in accordance with Kostas
et al(20).
Increased
hemolysis and/or red cell turnover might be blamed for the
elevated serum potassium and uric acid levels. Highest normal
value of uric acid in the beta-thalassemic patients, despite
the increased red cell turnover could be due to the increased
excretion of uric acid, evidenced by the high fractional excretion
in uric acid, which may be the result of the supra normal
proximal tubular function(21).
Aldosterone
is a mineralo-corticoid which acts on P cells of the distal
tubule and causes Na + reabsorption in exchange for K+ or
H+ secretion. This defect in potassium secretion is not clinically
apparent under normal circumstances, though hyperkalemia is
likely to manifest with mild degrees of renal impairment(22).
This might explain the slight elevation of potassium to upper
normal range in our study.
Furthermore,
there was also a statistically significant difference in serum
calcium between the control grouip and ß-thalassemiac
patients. The same observation for calcium level was also
reported by Saka et al(23).
On the
other hand a non-significant increase in the mean levels of
serum phosphorous was found in patients with ß-thalassemia
compared to the control group, This finding is similar to
that found by Kostas et al(20).
The ß-thalassemia
major results in severe anemia, which needs regular blood
transfusion. The combination of transfusion and chelating
therapy has dramatically extended the life expectancy of thalassemic
patients(22,23). On the other hand, frequent blood
transfusion in turn can lead to iron overload(24,25).
Hypocalcaemia
is a well known complication of iron overload(26).
Iron overload occurs either from the transfusion of red blood
cells or because there is increased absorption of iron from
the digestive tract. Both of these occur in thalassemia. Iron
overload also causes pituitary damage with hypogonadism, endocrine
complication, hypothyroidism and hypoparathyroidism is also
seen(27).
Parathyroid hormone which is secreted by the parathyroid gland
mobilizes calcium from bone(27,28).
A study
done by Desanctis 1995 showed that hypocalcemia due to hypoparathyroidism
is recognized as a later complication (age 16 year and above)
although in our study hypocalcemia was observed in a very
younger age. This could be attributed to poor patient compliance
due to poor education about the disease. An iron chelating
agent with its pump is not always available, and communications
between the thalassaemic centers and the patients are not
always easy.
| CONCLUSION
AND RECOMMENDATION |
- Pre
transfusion Hb value was suboptimal so more effort is required
to educate families on better compliance and more support
is required for donation of blood to thalassemic centers.
- Hypocalcaemia
is found in early age and might be due to unavailability
of a dysferoxamine pump or poor compliance.
- Serum
potassium was found to be in the upper normal range and
might be due to mild renal impairment, so future study should
be done on the effect of thalassemia on renal function.
- Screening
for thalassemia must be included and other tests pre marriage
are required since thalassemia is very common in the north
of Iraq.
- More
governmental & non-governmental support is required
focusing on availability of therapy, discovery of new cases,
as well asl education of families about thalassemia and
it's effect on growth.
- Zakaria M Al-Hawsawi, Ghousia
A Ismail, Hanan A. Al-Harbi, Zaki R Al-Sobhi. B-thalassemia
major, Saudi Medical Journal; 2003, 24 (9): 1027-1029
- Robert B.Gunn ,David N.Silvers
and Wendell F. Rosse Potassium permeability in ß -
Thalassemia minor red blood cells ,Clinical investigation,
1973; 51:1045-49
-
Mangalani M, Lokeshwar M.R, Banerjee R. Bone Histomorphometry
in Children and Adolescents with ß-Thalassemia Disease:
Iron-Associated Focal Osteomalacia, The Journal of Clinical
Endocrinology & Metabolism; 2003; 88(8) 3966-3972
-
Cooley TB, Lee P A series of cases of splenomegaly in children
with anemia and peculiar changes Trans Am Pediatr Soc, 1975;
37:29-30
-
David G. Nathan. Prospective on Thalassemia PEDIATRICS 1998;
Vol.102 No. 1 Supplement July, PP 281-283
-
Susanne R. Christoph B. Gunter H..Oral isobutyramide reduces
transfusion requirements in some patients with ß-thalassemia
2000, 96(10): 3357-63
-
David P. Steensma, James D. Hoyer and Virgil F. Fairbanks:
Hereditary red blood cell disorders in Middle Eastern patients.
Mayo Clin Proc.2001; 76:285-293
- Antia J. Cattin, Thalasssemia
: the facts and the controversies, Pediatr Nurs . 2003;
29(6): 447-451. www.medscape
.com/viewarticle /466838
- M.B. Agarwal Advances in Management
of Thalassemia, indian pediatrics; 2004; 41:989-992
- Jensen CE, Tuck SM, Agnew JE,
Koneru S, Morris RW, Morris RW, Yardumian A, Prescott E,
Hoffbrand AV, Wonke B: High prevalence of low bone mass
in thalassaemia major .B J Haemat 1998, 103:911-915
- Shalev O, Mogilner S and Shiner
E, Impaired erythrocyte calcium homeostasis in beta-thalassemia.
Blood; 1984; 64(2):564-6
- Alireza
Abdollah Shamshirsaz , Mir Reza Bekheirnia, Mohammad Kamgar1,
Metabolic and endocrinologic complications in beta-thalassemia
major: a multicenter study in Tehran .BMC Endocrine Disorders
2003, 3:4
-
Varly H. Practical clinical biochemistry; Willian, Heineman
Medical Books, London, 5th ed 1980, Volume(1) p.771
-
Gomorri G. Determination of serum phosphorous. J. Lab. Clin.
Med, 1942, 27:955
- Corns C and Ludman C Determination
of Calcium. Ann .Clin. Biochemistry 1987; 24:345
- Barham and Trinder. Estimation
of serum uric acid. Analyst. 1972; 97:142.
-
Danial ww. Biostatistics : a foundation for analysis health
science 1983; 3rd. John Wiley and Sons, USA
-
Pat Mahachoklertwattana, Vorachai Sirikulchayanonta, Ampaiwan
Chuansumrit. Bone Histomorphometry in Children and
Adolescents with ß-Thalassemia Disease: Iron-Associated
Focal Osteomalacia. The Journal of Clinical Endocrinology
& Metabolism. 2003; 88(8) 3966-3972
- Saka N, Sukur M, Bundak R, Anak
S, Neyzi O, Gedikoglu G Growth and puberty in thalassemia
major. J Pediatr Endocrinol Metab; 1995;8:181-186
- Kostas P. Katopodis, Moses S.
Elisaf, Haralampos A. Pappas. Renal abnormalities in patients
with sickle cell-beta thalassemia. J. of. Nephrology ;1997;Vol.10(3):163-167
- Soliman AT, El Banna N, Abdel
Fattah M, ElZalabani MM, Ansari BM
Bone mineral density in prepubertal children with beta-thalassemia:
correlation with growth and hormonal dataMetabolism. 1998
May; 47 (5) :541-8.
- Saka N, Sukur M, Bundak R, Anak
S, Neyzi O, gedikoglu G: Growth and puberty in thalassemia
major.J Pediatr Endocrinol Metab, 1995; 8:181-186
- Modell B, Letsky EA, Flynn DM,
Peto R, Weatherall DJ. Survival and desferrioxamine in thalassemia
major. BMJ , 1982; 284:1081-1084
- Jensen CE, et al . High prevalence
of low bone mass in thalassaemia
major.B J Haemat, 1998; 103:911-915
-
Vullo C, et al. Endocrine abnormalities in thalassemia.
Ann NY Acad Sci , 1990; 612:293-310
- Ali hasan dhary aljumaily, Shaimaa
khider. Prevalence of hypocalcemia among thalassemic patients
registered in IBN, 2005,
www.ajman.ac.ae/arabmed/abstracts/poster_session3.pdf
- Gentner
J.: Disorder of calcium and phosphorous homeostasis. Pediatric
Clin North Am.1990; 37:1441-1466
- Ganong W.S; Review of medical
physiology. 2002; 10th e
|
 |